scholarly journals Biological representation of chemicals using latent target interaction profile

2019 ◽  
Vol 20 (S24) ◽  
Author(s):  
Mohamed Ayed ◽  
Hansaim Lim ◽  
Lei Xie
Keyword(s):  
Machine Learning ◽  
Biological Activities ◽  
Learning Models ◽  
Target Interaction ◽  
Multi Scale ◽  
Chemical Structures ◽  
Chemical Fingerprints ◽  
Chemical Modulation ◽  
Genome Scale ◽  
Machine Learning Models

Abstract Background Computational prediction of a phenotypic response upon the chemical perturbation on a biological system plays an important role in drug discovery, and many other applications. Chemical fingerprints are a widely used feature to build machine learning models. However, the fingerprints that are derived from chemical structures ignore the biological context, thus, they suffer from several problems such as the activity cliff and curse of dimensionality. Fundamentally, the chemical modulation of biological activities is a multi-scale process. It is the genome-wide chemical-target interactions that modulate chemical phenotypic responses. Thus, the genome-scale chemical-target interaction profile will more directly correlate with in vitro and in vivo activities than the chemical structure. Nevertheless, the scope of direct application of the chemical-target interaction profile is limited due to the severe incompleteness, biasness, and noisiness of bioassay data. Results To address the aforementioned problems, we developed a novel chemical representation method: Latent Target Interaction Profile (LTIP). LTIP embeds chemicals into a low dimensional continuous latent space that represents genome-scale chemical-target interactions. Subsequently LTIP can be used as a feature to build machine learning models. Using the drug sensitivity of cancer cell lines as a benchmark, we have shown that the LTIP robustly outperforms chemical fingerprints regardless of machine learning algorithms. Moreover, the LTIP is complementary with the chemical fingerprints. It is possible for us to combine LTIP with other fingerprints to further improve the performance of bioactivity prediction. Conclusions Our results demonstrate the potential of LTIP in particular and multi-scale modeling in general in predictive modeling of chemical modulation of biological activities.

scholarly journals Multivariate Classification of Drugs using Parametric and Nonparametric Machine Learning Models

2020 ◽  
Vol 9 (3) ◽  
pp. 2021-2027
Keyword(s):  
Machine Learning ◽  
Drug Discovery ◽  
Biological Activities ◽  
Biological Effects ◽  
Recursive Feature Elimination ◽  
Drug Candidate ◽  
Learning Models ◽  
Machine Learning Models ◽  
Non Parametric

In pharmaceutical research, traditional drug discovery process is time consuming and expensive, where several compounds are experimentally tested for their biological activities. Series of lab experiments are conducted to analyze newly synthesized drug’s pharmaceutical activities and its biological effects on human. With every new drug discovery, the required clinical properties can be determined using machine learning models and this greatly reduces the experimental cost. This paper explores parametric and non-parametric machine learning models to classify administration properties of drugs and its toxicity. The multinomial classification of drugs was based on their physicochemical and ADMET properties. Balanced data samples were drawn from chEMBL and was pre-processed. Features were reduced using Recursive Feature Elimination and the attributes were ranked based on their importance to reduce highly correlated attributes. The performance of parametric and non-parametric machine learning models was analyzed on cheminformatic data that includes physiochemical, biological and pharmaceutical properties of the drug molecules. Selecting the potent drug candidate along with its administration properties greatly reduces wet lab experimental time and cost. Multiclass classification can be determined efficiently using non-parametric machine learning model. Optimal feature engineering, tuning hyperparameters and adopting hybrid algorithms would result in more accurate predictions in future for cheminformatics data.

scholarly journals Machine learning models identify molecules active against the Ebola virus in vitro

F1000Research ◽  
2017 ◽  
Vol 4 ◽  
pp. 1091 ◽  
Author(s):  
Sean Ekins ◽  
Joel S. Freundlich ◽  
Alex M. Clark ◽  
Manu Anantpadma ◽  
Robert A. Davey ◽  
...  
Keyword(s):  
Machine Learning ◽  
High Throughput ◽  
Ebola Virus ◽  
Biological Activities ◽  
European Medicines Agency ◽  
Infection Model ◽  
Learning Models ◽  
Compound Libraries ◽  
Machine Learning Models

The search for small molecule inhibitors of Ebola virus (EBOV) has led to several high throughput screens over the past 3 years. These have identified a range of FDA-approved active pharmaceutical ingredients (APIs) with anti-EBOV activity in vitro and several of which are also active in a mouse infection model. There are millions of additional commercially-available molecules that could be screened for potential activities as anti-EBOV compounds. One way to prioritize compounds for testing is to generate computational models based on the high throughput screening data and then virtually screen compound libraries. In the current study, we have generated Bayesian machine learning models with viral pseudotype entry assay and the EBOV replication assay data. We have validated the models internally and externally. We have also used these models to computationally score the MicroSource library of drugs to select those likely to be potential inhibitors. Three of the highest scoring molecules that were not in the model training sets, quinacrine, pyronaridine and tilorone, were tested in vitro and had EC50 values of 350, 420 and 230 nM, respectively. Pyronaridine is a component of a combination therapy for malaria that was recently approved by the European Medicines Agency, which may make it more readily accessible for clinical testing. Like other known antimalarial drugs active against EBOV, it shares the 4-aminoquinoline scaffold. Tilorone, is an investigational antiviral agent that has shown a broad array of biological activities including cell growth inhibition in cancer cells, antifibrotic properties, α7 nicotinic receptor agonist activity, radioprotective activity and activation of hypoxia inducible factor-1. Quinacrine is an antimalarial but also has use as an anthelmintic. Our results suggest data sets with less than 1,000 molecules can produce validated machine learning models that can in turn be utilized to identify novel EBOV inhibitors in vitro.

scholarly journals Machine learning models identify molecules active against the Ebola virus in vitro

F1000Research ◽  
2015 ◽  
Vol 4 ◽  
pp. 1091 ◽  
Author(s):  
Sean Ekins ◽  
Joel S. Freundlich ◽  
Alex M. Clark ◽  
Manu Anantpadma ◽  
Robert A. Davey ◽  
...  
Keyword(s):  
Machine Learning ◽  
High Throughput ◽  
Ebola Virus ◽  
Biological Activities ◽  
European Medicines Agency ◽  
Infection Model ◽  
Learning Models ◽  
Compound Libraries ◽  
Machine Learning Models

The search for small molecule inhibitors of Ebola virus (EBOV) has led to several high throughput screens over the past 3 years. These have identified a range of FDA-approved active pharmaceutical ingredients (APIs) with anti-EBOV activity in vitro and several of which are also active in a mouse infection model. There are millions of additional commercially-available molecules that could be screened for potential activities as anti-EBOV compounds. One way to prioritize compounds for testing is to generate computational models based on the high throughput screening data and then virtually screen compound libraries. In the current study, we have generated Bayesian machine learning models with viral pseudotype entry assay and the EBOV replication assay data. We have validated the models internally and externally. We have also used these models to computationally score the MicroSource library of drugs to select those likely to be potential inhibitors. Three of the highest scoring molecules that were not in the model training sets, quinacrine, pyronaridine and tilorone, were tested in vitro and had EC50 values of 350, 420 and 230 nM, respectively. Pyronaridine is a component of a combination therapy for malaria that was recently approved by the European Medicines Agency, which may make it more readily accessible for clinical testing. Like other known antimalarial drugs active against EBOV, it shares the 4-aminoquinoline scaffold. Tilorone, is an investigational antiviral agent that has shown a broad array of biological activities including cell growth inhibition in cancer cells, antifibrotic properties, α7 nicotinic receptor agonist activity, radioprotective activity and activation of hypoxia inducible factor-1. Quinacrine is an antimalarial but also has use as an anthelmintic. Our results suggest data sets with less than 1,000 molecules can produce validated machine learning models that can in turn be utilized to identify novel EBOV inhibitors in vitro.

scholarly journals Machine learning models identify molecules active against the Ebola virus in vitro

F1000Research ◽  
2016 ◽  
Vol 4 ◽  
pp. 1091 ◽  
Author(s):  
Sean Ekins ◽  
Joel S. Freundlich ◽  
Alex M. Clark ◽  
Manu Anantpadma ◽  
Robert A. Davey ◽  
...  
Keyword(s):  
Machine Learning ◽  
High Throughput ◽  
Ebola Virus ◽  
Biological Activities ◽  
European Medicines Agency ◽  
Infection Model ◽  
Learning Models ◽  
Compound Libraries ◽  
Machine Learning Models

The search for small molecule inhibitors of Ebola virus (EBOV) has led to several high throughput screens over the past 3 years. These have identified a range of FDA-approved active pharmaceutical ingredients (APIs) with anti-EBOV activity in vitro and several of which are also active in a mouse infection model. There are millions of additional commercially-available molecules that could be screened for potential activities as anti-EBOV compounds. One way to prioritize compounds for testing is to generate computational models based on the high throughput screening data and then virtually screen compound libraries. In the current study, we have generated Bayesian machine learning models with viral pseudotype entry assay and the EBOV replication assay data. We have validated the models internally and externally. We have also used these models to computationally score the MicroSource library of drugs to select those likely to be potential inhibitors. Three of the highest scoring molecules that were not in the model training sets, quinacrine, pyronaridine and tilorone, were tested in vitro and had EC50 values of 350, 420 and 230 nM, respectively. Pyronaridine is a component of a combination therapy for malaria that was recently approved by the European Medicines Agency, which may make it more readily accessible for clinical testing. Like other known antimalarial drugs active against EBOV, it shares the 4-aminoquinoline scaffold. Tilorone, is an investigational antiviral agent that has shown a broad array of biological activities including cell growth inhibition in cancer cells, antifibrotic properties, α7 nicotinic receptor agonist activity, radioprotective activity and activation of hypoxia inducible factor-1. Quinacrine is an antimalarial but also has use as an anthelmintic. Our results suggest data sets with less than 1,000 molecules can produce validated machine learning models that can in turn be utilized to identify novel EBOV inhibitors in vitro.

scholarly journals Machine learning-guided discovery and design of non-hemolytic peptides

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Fabien Plisson ◽  
Obed Ramírez-Sánchez ◽  
Cristina Martínez-Hernández
Keyword(s):  
Machine Learning ◽  
Clinical Trials ◽  
Outlier Detection ◽  
Biological Activities ◽  
Peptide Sequence ◽  
Biological Information ◽  
Detection Methods ◽  
Gradient Boosting ◽  
Learning Models ◽  
Machine Learning Models

Abstract Reducing hurdles to clinical trials without compromising the therapeutic promises of peptide candidates becomes an essential step in peptide-based drug design. Machine-learning models are cost-effective and time-saving strategies used to predict biological activities from primary sequences. Their limitations lie in the diversity of peptide sequences and biological information within these models. Additional outlier detection methods are needed to set the boundaries for reliable predictions; the applicability domain. Antimicrobial peptides (AMPs) constitute an extensive library of peptides offering promising avenues against antibiotic-resistant infections. Most AMPs present in clinical trials are administrated topically due to their hemolytic toxicity. Here we developed machine learning models and outlier detection methods that ensure robust predictions for the discovery of AMPs and the design of novel peptides with reduced hemolytic activity. Our best models, gradient boosting classifiers, predicted the hemolytic nature from any peptide sequence with 95–97% accuracy. Nearly 70% of AMPs were predicted as hemolytic peptides. Applying multivariate outlier detection models, we found that 273 AMPs (~ 9%) could not be predicted reliably. Our combined approach led to the discovery of 34 high-confidence non-hemolytic natural AMPs, the de novo design of 507 non-hemolytic peptides, and the guidelines for non-hemolytic peptide design.

scholarly journals Synthqa - Hierarchical Machine Learning-Based Protein Quality Assessment

2021 ◽  
Author(s):  
Mikhail Korovnik ◽  
Kyle Hippe ◽  
Jie Hou ◽  
Dong Si ◽  
Kiyomi Kishaba ◽  
...  
Keyword(s):  
Machine Learning ◽  
Protein Structure ◽  
Quality Assessment ◽  
Protein Structures ◽  
Hierarchical Architecture ◽  
Learning Models ◽  
Single Model ◽  
Multi Scale ◽  
The Relationship ◽  
Machine Learning Models

ABSTRACTMotivationIt has been a challenge for biologists to determine 3D shapes of proteins from a linear chain of amino acids and understand how proteins carry out life’s tasks. Experimental techniques, such as X-ray crystallography or Nuclear Magnetic Resonance, are time-consuming. This highlights the importance of computational methods for protein structure predictions. In the field of protein structure prediction, ranking the predicted protein decoys and selecting the one closest to the native structure is known as protein model quality assessment (QA), or accuracy estimation problem. Traditional QA methods don’t consider different types of features from the protein decoy, lack various features for training machine learning models, and don’t consider the relationship between features. In this research, we used multi-scale features from energy score to topology of the protein structure, and proposed a hierarchical architecture for training machine learning models to tackle the QA problem.ResultsWe introduce a new single-model QA method that incorporates multi-scale features from protein structures, utilizes the hierarchical architecture of training machine learning models, and predicts the quality of any protein decoy. Based on our experiment, the new hierarchical architecture is more accurate compared to traditional machine learning-based methods. It also considers the relationship between features and generates additional features so machine learning models can be trained more accurately. We trained our new tool, SynthQA, on the CASP dataset (CASP10 to CASP12), and validated our method on 33 targets from the latest CASP 14 dataset. The result shows that our method is comparable to other state-of-the-art single-model QA methods, and consistently outperforms each of the 14 used features.Availabilityhttps://github.com/Cao-Labs/[email protected]

Improving XGBoost with Imagination Sampling

2020 ◽  
Vol 2 (1) ◽  
pp. 3-6
Author(s):  
Eric Holloway
Keyword(s):  
Machine Learning ◽  
General System ◽  
Learning Models ◽  
Starting Point ◽  
Machine Learning Models

Imagination Sampling is the usage of a person as an oracle for generating or improving machine learning models. Previous work demonstrated a general system for using Imagination Sampling for obtaining multibox models. Here, the possibility of importing such models as the starting point for further automatic enhancement is explored.

Sign in / Sign up

Export Citation Format

Share Document